Management Board ofGenomtec S.A. (The "Issuer") informs that as of today, i.e. on April 22,2021, a patent application has been filed for the technology developedby the Issuer.Thedescribed application concerns the proprietary set of primers, thediagnostic method and the reaction mixture composition for the geneticdiagnosis of MRSA (methicillin-resistant staphylococcus aureus) in theLAMP technique. The application was filed with the Polish Patent Office,Republic of Poland.Methicillin-resistantstaphylococcal strains are a common cause of hospital-acquiredinfections and pose a significant problem due to the difficulties intheir treatment. The microorganism's developed resistance causes nosensitivity to all beta-lactam group of antibiotics - includingpenicillins, cephalosporins, monobactams and carbapenems. The developedset of primers is a key element of the diagnostic method based on theLAMP technology utilised by the Issuer. Primers initiate theamplification reaction by recognizing a specific fragment of thepathogen's genome. The described patent application prevents the risk ofusing the same set of primers in an assay by competitors.TheIssuer's Management Board decided that filing the described patentapplication is a confidential information, as for an entity operating onthe molecular diagnostics market it is necessary to effectively protectintellectual property and designs. Properly secured intellectualproperty and designs may constitute the Issuer's competitive advantage,allowing safer commercialization under condition that full protection isensured on selected markets.Inthe opinion of the Management Board, a high level of intellectualproperty protection will also provide the Company with a n advantageousnegotiating position before signing any commercial contracts withselected partners as part of the commercialization strategyimplementation.Diagnosisof bacterial infections, including MRSA, is one of the key areas oftechnology developed by the Issuer. For these reasons, in the opinion ofthe Management Board, this information meets the criteria ofconfidential information described in Art. 7 sec. 1 MAR.